Clinical TrialJul 9, 2026, 07:01 AM
INmune Bio XPro Phase 2 Alzheimer's Data Shows Early Treatment Effects
AI Summary
INmune Bio announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer’s disease. The data showed early, concordant treatment-related effects across independent white matter and gray matter imaging endpoints, with statistically significant improvements in white matter myelin integrity at Week 24 (p < 0.01). These findings support the biologic activity of selective soluble TNF inhibition and will be presented at the Alzheimer’s Association International Conference (AAIC) 2026. The company believes these results reinforce confidence in XPro's potential, especially given its FDA Fast Track designation.
Key Highlights
- XPro Phase 2 study in early Alzheimer's disease showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24.
- White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 (p < 0.01).
- Larger effects were observed in patients selected using the company’s biomarker enrichment strategy.
- Data supports biologic activity of selective soluble TNF inhibition and early, concordant treatment-related effects across independent white and gray matter imaging endpoints.
- The findings will be presented at the Alzheimer’s Association International Conference (AAIC) 2026.
- XPro1595 has FDA Fast Track designation and is positioned for an integrated Phase 2b/3 registrational program.
Price Impact
More from INMB